Part of the renowned Braunwald family of references, Clinical Lipidology: A Companion to Braunwald’s Heart Disease provides today’s clinicians with clear, authoritative guidance on the therapeutic management of patients with high cholesterol levels and other atherogenic lipid disorders. An invaluable resource for cardiologists, lipidologists, endocrinologists, and internal medicine physicians, this one-stop reference covers everything from basic science and the pathogenesis of atherothrombotic disease to risk assessment and the latest therapy options. Now fully updated from cover to cover, the 3rd Edition offers unparalleled coverage of lipidology in an accessible and user-friendly manner.
Key Features
Thoroughly covers the assessment, diagnosis, and treatment of patients with elevated levels of lipids and lipoproteins, including all the latest research-based recommendations, therapeutic breakthroughs, and related clinical advances. Presents the latest data on clinical guidelines, risk assessments, and established and emerging pharmacologic and nonpharmacologic therapies—all from internationally recognized experts in the field. Features condensed, streamlined content that focuses on clinical applications and applying concepts to the practice setting. Chapters have now been completely reorganized into sections on risk assessment; therapy; new and evolving therapeutic targets and platforms; and special populations. Includes new chapters on Polygenic Risk Scores; Inclisiran; Bempedoic Acid; Selective Peroxisome Proliferator–Activated Receptor–a Modulator: Pemafibrate; Evolving Therapeutic Targets: Lp(a), ANGPTL3, and ApoC-III; New Therapeutic Platforms: Gene Therapy and Genome Editing; and more. Contains new or expanded content on inflammation; genetic testing; troponins for risk assessment; statins and role of bile acid sequestrants, niacin, and fibrates; mAbs; CANTOS and CIRT; colchicine; IL-6; and cellular, molecular, and genetic therapy. Provides treatment algorithms throughout, as well as case vignettes that highlight the most common clinical questions in each chapter. Incorporates the latest guidelines from the AHA, ACC, ESC, and EAS, as well as future directions for ongoing research and emerging applications. Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. -도서목차-
Section 1 Basic Mechanisms
1. Human Plasma Lipoprotien Metabolism 2. Regulation and Clearance of Apolipoprotein B–Containing Lipoproteins 3. Absorption and Excretion of Intestinal Cholesterol and Other Sterols 4. High-Density Lipoprotein Metabolism 5. Lipoproteins: Mechanisms for Atherogenesis and Progression of Atherothrombotic Disease 6. Impact of Rare and Common Genetic Variants on Lipoprotein Metabolism 7. Lipoprotein Oxidation: Mechanisms and Biotheranostic Applications
Section 2 Risk Assessment
8. Cholesterol: Concentration, Ratio, and Particle Number 9. High-Density Lipoprotein Cholesterol and Triglycerides in Coronary Heart Disease Risk Assessment 10. Lipoprotein(a) 11. Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia 12. Use of High Sensitivity C-Reactive Protein for Risk Assessment 13. Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease 14. Emerging Assays 15. Imaging Atherosclerosis for Risk Stratification by Cardiac Computed Tomography or Carotid Ultrasound
Section 3 Therapy
16. Overview of General Approach to Management of Elevated Low-Density Lipoprotein Cholesterol and Mixed Dyslipidemia, High Triglycerides, and Low High-Density Lipoprotein Cholesterol 17. Treatment Guidelines Overview 18. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease 19. Exercise and Lipids 20. Weight Loss 21. Statins 22. Bile Acid Sequestrants 23. Cholesterol Absorption Inhibitors 24. Niacin (Nicotinic Acid) 25. Fibrates 26. Omega-3 Fatty Acids 27. Combination Therapy for Dyslipidemia 28. Nutriceuticals and Functional Foods for Cholesterol Reduction 29. Evolving Targets of Therapy: Cholesteryl Ester Transfer Protein Inhibition 30. Evolving Targets of Therapy: Proprotein Convertase Subtilisin/Kexin 9 Inhibition 31. Evolving Targets of Therapy: Inflammation as a Method to Predict and Prevent Cardiovascular Events 32. Invasive Imaging Modalities and Atherosclerosis: Intravascular Ultrasound 33. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound 34. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Magnetic Resonance Imaging and Positron Emission Tomography Imaging 35. Special Patient Populations: Diabetes and Metabolic Syndrome 36. Special Patient Populations: Women and Elderly 37. Special Patient Populations: Children and Adolescents 38. Special Patient Populations: Familial Hypercholesterolemia and other Severe Hypercholesterolemias 39. Special Patient Populations: Acute Coronary Syndromes 40. Special Patient Populations: Transplant Recipients 41. Special Patient Populations: Chronic Kidney Disease 42. Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups 43. Special Patient Populations: Human Immunodeficiency Patients 44. Therapeutic Targeting of High-Density Lipoprotein Metabolism
기타 도서와 관련된 문의사항은 고객센터(02-854-2738) 또는 저희 성보의학서적 홈페이지내 도서문의 게시판에 문의바랍니다. 감사합니다. 성보의학서적 "http://www.medcore.kr